Tirzepatide vs tirzepatide

Zepbound vs Mounjaro

Like Ozempic and Wegovy, this is a same-molecule comparison. Zepbound and Mounjaro are both tirzepatide from Eli Lilly. Zepbound is approved for weight management (and obstructive sleep apnea in obesity); Mounjaro is approved for type 2 diabetes.

The pharmacology is the same dual GIP/GLP-1 agonism; the differences are approval, coverage, and which condition you are being treated for.

Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.

At a glance

ZepboundMounjaro
Active drugTirzepatideTirzepatide
Approved forWeight management; OSA in obesityType 2 diabetes
MechanismGLP-1 + GIP dual agonistGLP-1 + GIP dual agonist
DosingWeekly injectionWeekly injection
Weight loss useOn-labelOff-label

Are they interchangeable?

Pharmacologically they are the same molecule, but they are prescribed and covered for different approved uses. Whether you receive one or the other depends on your diagnosis and your insurance, decided with your prescriber.

Which for whom

  • If you are treated for obesity, Zepbound is the on-label option; coverage for weight management is uneven.
  • If you have type 2 diabetes, Mounjaro may be covered through your diabetes benefit.
  • This is a prescriber and coverage decision, not a self-selection.
The off-ramp angle

Which holds weight better after you stop?

Because both are tirzepatide, the off-ramp is identical. Stopping either lets appetite hormones rebound while metabolic rate stays low, so weight tends to climb back without a maintenance plan.

FAQ

Frequently asked questions

Is Zepbound the same as Mounjaro?

Yes, both are tirzepatide. Zepbound is approved for weight management; Mounjaro is approved for type 2 diabetes. Same molecule, different label.

Sources & further reading

Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.

  1. [1]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC
  2. [2]Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysisNIH/PMC

The drugs

Related guides